Bone Therapeutics, SA, an international biopharmaceutical company focused on innovative cell therapy products for the treatment of bone diseases, has successfully closed a Series D funding which raised 7.7 million Euros from current investors and the Walloon Region. The company is headquartered at the Biopôle of Gosselies, which is south of Brussels, Belgium.
Bone Therapeutics Raises 7.7 Million Euros
1 min read Premium comments
Secondary
The funds raised will be used to accelerate the development of Bone Therapeutics’ bone cell therapy pipeline, as well as sustain the ongoing Phase III clinical trials for its lead product PREOB. PREOB is an autologous bone cell therapy product which is in Phase III clinical trials for the treatment of osteonecrosis and non-union fractures. The company’s cell therapy approach seeks to significantly improve upon current standard of care for bone diseases. All Bone Therapeutics’ cell products are osteoblastic (i.e., bone-forming) and require a minimally invasive administration technique, avoiding the need for surgery.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.